complement c5

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Zilucoplan(PEG2) is a derivative of Zilucoplan where the linker component has been substituted with PEG2 instead of PEG24. This compound acts as an effective inhibitor of complement component 5 (C5).

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

ARC1905, a non-PEGylated naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5.

Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor, is used in the study of immune-mediated necrotising myopathy (IMNM) [1] [2].

Gefurulimab (ALXN-1720) is a human-derived bispecific antibody that targets complement C5 and albumin, specifically binding to C5 to inhibit its activation [1].

Pexelizumab (h5G1.1-SC), a humanized scFv monoclonal antibody, targets the C5 complement component, thereby inhibiting apoptosis and leukocyte infiltration. It is utilized in researching cerebral ischemia-reperfusion (IR) injury and myocardial infarction [1] [2].

Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 activation [1].

Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2].

Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody targeting complement protein C5, combined with the domains 1-5 of complement factor H (FH1-5). It exhibits anti-inflammatory and immunomodulatory properties. The isotype control for Vensobafusp alfa can be referred to as human IgG4(S228P) kappa.

Boc-Leu-Gly-Arg-AMC is a specific fluorogenic substrate designed for the enzymatic detection and quantification of complement component C3/C5 convertases, coagulation factor Xa, and soybean trypsin-like enzyme activity. Boc-Leu-Gly-Arg-AMC is also susceptible to hydrolysis by macropain, a high molecular weight thiol proteinase isolated from human erythrocytes, making it a versatile tool for enzymatic assays.